Patents by Inventor Ravi K. Erukulla

Ravi K. Erukulla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified ether glyceroglycolipids
    Patent number: 6573246
    Abstract: This invention provides lipids having: 1) a glycerol backbone; 2) a hydrocarbon chain, preferably saturated and containing 16 or 18 carbon atoms, attached to C-1 of the backbone by an ether linkage, 3) a methyl group attached to C-2 of the backbone, preferably by an ether linkage; and, 4) a sugar attached to C-3 of the glycerol backbone in either the alpha or beta anomeric configuration, the sugar being altered by modification of, or substitution for, one or more of its hydroxyl groups. Also provided herein are ether-lipid-containing compositions, as well as methods of administering such compositions to animals, for example, those afflicted with cancers, as well as various other diseases and disorders.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: June 3, 2003
    Assignees: The Liposome Company, Inc., The Research Foundation of the City University of New York
    Inventors: Robert Bittman, Ravi K. Erukulla, Andrew C. Peters, Eric G. Mayhew
  • Peptide-lipid conjugates, liposomes and lipsomal drug delivery
    Patent number: 6339069
    Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: January 15, 2002
    Assignee: Elan PharmaceuticalsTechnologies, Inc.
    Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly, Patrick L. Ahl
  • Modified ether glyceroglycolipids
    Patent number: 6153736
    Abstract: This invention provides lipids having: 1) a glycerol backbone; 2) a hydrocarbon chain, preferably saturated and containing 16 or 18 carbon atoms, attached to C-1 of the backbone by an ether linkage; 3) a methyl group attached to C-2 of the backbone, preferably by an ether linkage; and, 4) a sugar attached to C-3 of the glycerol backbone in either the alpha or beta anomeric configuration, the sugar being altered by modification of, or substitution for, one or more of its hydroxyl groups. Also provided herein are ether-lipid-containing compositions, as well as methods of administering such compositions to animals, for example, those afflicted with cancers, as well as various other diseases and disorders.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: November 28, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Robert Bittman, Ravi K. Erukulla, Andrew C. Peters, Eric G. Mayhew
  • Liposomal peptide-lipid conjugates and delivery using same
    Patent number: 6143716
    Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: November 7, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly
  • Peptide-lipid conjugates
    Patent number: 6087325
    Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: July 11, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly